Comparison of the Breast Tumor Microenvironment

Triple Negative Breast Cancer Clinical Trial

Official title:

Differential Comparison of the Breast Tumor Microenvironment Between Luminal A and Triple Negative Breast Cancer With and Without Radiation Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03165487
• Other study ID #: AAAO7708
• Status: Recruiting
• Start date: September 28, 2017
• Est. completion date: December 31, 2026

Study information

• Verified date: June 2024
• Source: Columbia University
• Contact: Eileen Connolly, MD
• Phone: 212-305-5050
• Email: epc2116[@]cumc.columbia.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of the project is to identify a molecular signature of tumor stroma from "normal" adjacent breast tissue obtained prospectively at the time of breast conserving surgery before and after receiving intraoperative radiation therapy (IORT) in subjects that have luminal A and triple negative breast cancer. IORT is considered as being standard of care.

Description:

There is evidence that the normal tissue around a tumor plays a role in determining how the tumor behaves, including how it will respond to treatments and how likely it is to recur. In breast cancer, radiation is used to decrease the chance of recurrence in the area where the tumor is removed. This risk of recurrence varies between different types of breast cancer. The investigators seek to study the proteins produced in normal tissue surrounding breast tumors. The tissue will be taken from women who are receiving radiation to the breast at the time of their surgery (known as intraoperative radiation), one specimen taken before radiation and one after. A new process will be used to stabilize the tissue rapidly and allow the proteins to be identified before they break down. This will allow us to identify differences in the proteins produced by cells before and after radiation and between two types of breast cancers, luminal A (less likely to recur) and triple negative (more likely to recur). Identifying these differences in proteins may allow them to be used in the future as markers to predict the likelihood of tumors recurring.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Female, age greater than or equal to 40

• Core biopsy proven invasive breast carcinoma or ductal carcinoma in situ (DCIS), all subtypes excluding invasive lobular carcinoma due to increased risk for multifocal disease

• Human epidermal growth factor receptor 2 (HER2) negative regardless of hormone receptor status

• Clinically less than or equal to 3cm unifocal lesion

• Clinically node negative

• Must have diagnostic mammogram performed within last 6 months

• Eastern Cooperative Oncology Group Performance Status (ECOG PS) less than or equal to 1

• Appropriate renal, liver, and hematologic lab values

• Ability to give informed consent

Exclusion Criteria:

• Multifocal disease

• Clinically N1 disease at diagnosis

• Invasive lobular carcinoma

• Metastatic disease

• Patients for whom RT would be contraindicated (e.g., connective tissue disorder or prior ipsilateral breast radiation)

• Patients with known BRCA1/2 mutations

• Pregnant or nursing

Related Conditions & MeSH terms

• Breast Neoplasms
• Hormone Receptor Positive Malignant Neoplasm of Breast
• Neoplasms
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Other:
• Breast tissue collection
During Breast Conservation Surgery, one sample will be collected before and after IORT.
• Blood sample collection
Blood will be collected before and after IORT, and at the two week follow-up.

Locations

Country	Name	City	State
United States	Columbia University Irving Medical Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Columbia University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects with significant mean percent change in Tumor Infiltrating Lymphocytes (TILs)	This outcome measure is designed to measure the amount of TILs in newly diagnosed luminal A and Triple Negative Breast Cancer (TNBC) tumors. The mean percent change in TILS in tumor tissue from initial core biopsy samples will be compared with pathology samples from definitive surgery after IORT between the two different breast cancer sub-types.	Two weeks